The Food and Drug Administration has accepted for review an oral suspension seizure drug made by Eisai, a Japanese drugmaker with a presence in Research Triangle Park.
The FDA said it would review Banzel, a drug that is intended for children and adults who have trouble swallowing tablets.
The FDA's acceptance is the first step in the drug approval process. Eisai submitted Banzel for review in late April.
In May, Eisai opened its $100 million, 65,000-square-foot manufacturing facility in Research Triangle Park.